Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. 1993

J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
Department of Clinical Chemistry, University of Helsinki, Finland.

It is well documented that the calcitonin gene area in the short arm of chromosome 11 is hypermethylated in most acute leukemias as well as in chronic lymphatic leukemia. In contrast, the gene is normally methylated during the chronic phase of the chronic myeloid leukemia but turns hypermethylated as the disease escalates. As the methylation of the calcitonin gene correlates with the disease activity in chronic myeloid leukemia, it seemed worthwhile to study the gene methylation in other premalignant hematologic conditions with a potential to terminate in fulminant acute leukemia. We report here on the calcitonin gene methylation in patients with myelodysplastic syndromes (MDS) using a methylation sensitive restriction enzyme HpaII and standard Southern blotting techniques. Bone marrow aspirates from a total of 26 MDS patients were studied. In 24 of these patients, the calcitonin gene was hypermethylated. There was no correlation between the methylation status and the morphological stage of the disease. All six patients with a blast count < 5% had a hypermethylated gene. Of the 19 patients with a blast count > 5%, 17 were hypermethylated only two having normal methylation status of the gene. It appears that the hypermethylation of the calcitonin gene area in the short arm of chromosome 11 may be an early event in the pathogenesis of the myelodysplastic syndromes. The methylation analysis may thus be of value as a diagnostic tool in MDS but an abnormal methylation pattern does not seem to have a direct relation with the degree of blast infiltration.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008745 Methylation Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed) Methylations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000753 Anemia, Refractory A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy. Refractory Anemia,Anemias, Refractory,Refractory Anemias
D000754 Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells. Leukemia, Smoldering,RAEB,RAEM,Refractory Anemia with Excess of Blasts,Leukemia, Smouldering,Leukemias, Smoldering,Smoldering Leukemia,Smoldering Leukemias,Smouldering Leukemia

Related Publications

J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
October 1995, Leukemia research,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
August 1997, Blood,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
December 1998, Leukemia & lymphoma,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
January 1997, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
July 2002, Chinese medical journal,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
January 1991, Nouvelle revue francaise d'hematologie,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
January 2008, The Indian journal of medical research,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
February 1999, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
March 2022, Chinese journal of integrative medicine,
J Ihalainen, and S Pakkala, and E R Savolainen, and S E Jansson, and A Palotie
January 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!